As ER binding and cell proliferation show a dependency on FOXA1 even in an endocrine-resistant setting (95-97), FOXA1 represents an attractive (yet currently undruggable) therapeutic target in breast cancer, with FOXA1 inhibitors potentially also effective where resistance to ER antagonists has emerged. The gene discussed is ESR1; the disease is breast carcinoma.